MG
RARE icon

Marex Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Marex Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$344K Sell
10,296
-403
-4% -$10K ﹤0.01% 812
2026
Q1 		$224K Buy
10,699
+1,041
+11% +$23.4K ﹤0.01% 872
2025
Q4 		$222K Buy
+9,658
New +$318K ﹤0.01% 810

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Marex Group's RARE Position: Q2 2026 in Review

Marex Group reduced its Ultragenyx Pharmaceutical (RARE) stake by 3.8% in Q2 2026, selling an estimated $10K and leaving 10,296 shares worth $344K. The position accounts for ﹤0.01% of the portfolio, ranked #812.

Marex Group first reported a position in RARE in Q4 2025 and has held it in 3 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Marex Group held 10,296 shares of Ultragenyx Pharmaceutical worth $344K as of Q2 2026.
  • Marex Group sold 403 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $10K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Marex Group's portfolio in Q2 2026, its #812 holding.
  • Marex Group first reported a position in Ultragenyx Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.